Inovio Pharmaceuticals Inc (INO) Company Profile & Statistics

Inovio Pharmaceuticals Inc
INO
(Nasdaq - US)
Closed
10.22
-0.85 (-7.68%)
in:usd•As of: Apr 18, 2024 15:59 UTC -4
Open
11.01
High
11.01
Low
10.14

About Inovio Pharmaceuticals Inc

CEO

Jacqueline E. Shea

Headquarters

660 w. germantown pike, suite 110

plymouth meeting, pa 19462, united states

Auditor

Ernst & YoungLLP

Employees

122

Share Holders

Website

www.inovio.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Inovio Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	238.84M
Enterprise Value	241.30M
Enterprise Value/EBITDA (ttm)	-1.82
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.87
Price to Sales (ttm)	270.62
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-14975.42%
Profit Margin (ttm)	-21045.74%
Return on Equity (ttm)	-79.86%
Return on Invested Capital (ttm)	-87.25%
Return on Assets (ttm)	-57.71%

Income Statement

Revenue (ttm)	832.00K
Revenue Per Share (ttm)	0.04
Gross Profit (ttm)	832.00K
EBITDA (ttm)³	-132.62M
Net Income Avi to Common (ttm)	-135.12M
Diluted EPS (ttm)	-7.56

Share Statistics

Beta (5Y Monthly)	1.11
52-Week Change	-3.38%
S&P500 52-Week Change	20.62%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	23.37M
Dividend Yield	0.00%
Float ⁴	22.93M
% Held by Insiders	1.90%
% Held by Institutions	26.79%

Balance Sheet

Total Cash (mrq)	145.29M
Total Cash Per Share (mrq)	6.22
Total Debt (mrq)	16.77M
Total Debt/Equity (mrq)	14.29%
Current Ratio (mrq)	3.60%
Quick Ratio (mrq)	3.60%
Book Value Per Share (mrq)	5.15

Cash Flow

Operating Cash Flow Per Share (ytd)	-5.61
Free Cash Flow (ytd)	-118.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Inovio Pharmaceuticals Inc

Trade With A Regulated Broker